Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroendocrine Tumors | 10 | 2025 | 659 | 3.130 |
Why?
|
Pancreatic Neoplasms | 24 | 2024 | 5444 | 2.030 |
Why?
|
Intestinal Neoplasms | 3 | 2023 | 314 | 1.370 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2022 | 957 | 1.200 |
Why?
|
Paraganglioma | 3 | 2024 | 143 | 1.090 |
Why?
|
Pheochromocytoma | 3 | 2024 | 327 | 1.040 |
Why?
|
Somatostatin | 4 | 2025 | 459 | 1.000 |
Why?
|
Carcinoma, Pancreatic Ductal | 10 | 2024 | 1757 | 0.830 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2024 | 732 | 0.830 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 90 | 0.800 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2025 | 11876 | 0.720 |
Why?
|
Adenocarcinoma | 8 | 2023 | 6359 | 0.630 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 388 | 0.580 |
Why?
|
Stomach Neoplasms | 3 | 2023 | 1480 | 0.530 |
Why?
|
Leucovorin | 5 | 2024 | 644 | 0.520 |
Why?
|
Intestine, Small | 1 | 2021 | 1217 | 0.490 |
Why?
|
Fluorouracil | 5 | 2024 | 1652 | 0.410 |
Why?
|
Endometrial Neoplasms | 1 | 2022 | 1381 | 0.400 |
Why?
|
Paclitaxel | 7 | 2024 | 1728 | 0.390 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2024 | 3667 | 0.380 |
Why?
|
Organoplatinum Compounds | 4 | 2017 | 406 | 0.380 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13644 | 0.350 |
Why?
|
Germ Cells | 3 | 2022 | 644 | 0.320 |
Why?
|
Rectal Neoplasms | 1 | 2017 | 1183 | 0.300 |
Why?
|
Diethylstilbestrol | 1 | 2005 | 85 | 0.250 |
Why?
|
Estrogens, Non-Steroidal | 1 | 2005 | 52 | 0.250 |
Why?
|
Deoxycytidine | 3 | 2024 | 886 | 0.250 |
Why?
|
Albumins | 3 | 2024 | 578 | 0.250 |
Why?
|
Liver Neoplasms | 2 | 2015 | 4356 | 0.200 |
Why?
|
Infertility, Male | 1 | 2005 | 396 | 0.200 |
Why?
|
Hypertension | 1 | 2022 | 8616 | 0.200 |
Why?
|
Americas | 1 | 2022 | 110 | 0.200 |
Why?
|
Succinate Dehydrogenase | 1 | 2022 | 148 | 0.190 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.180 |
Why?
|
Cells | 1 | 2022 | 162 | 0.180 |
Why?
|
Atlases as Topic | 1 | 2022 | 247 | 0.180 |
Why?
|
Neutropenia | 2 | 2023 | 895 | 0.170 |
Why?
|
Helicobacter pylori | 1 | 2023 | 380 | 0.170 |
Why?
|
Helicobacter Infections | 1 | 2023 | 390 | 0.160 |
Why?
|
Humans | 46 | 2025 | 766812 | 0.160 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2023 | 343 | 0.160 |
Why?
|
Edema | 1 | 2023 | 764 | 0.160 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 630 | 0.160 |
Why?
|
Esophageal Neoplasms | 2 | 2024 | 1661 | 0.160 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 2902 | 0.150 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1026 | 0.150 |
Why?
|
Genomics | 4 | 2024 | 5922 | 0.150 |
Why?
|
Aged | 20 | 2025 | 171344 | 0.150 |
Why?
|
Germ-Line Mutation | 3 | 2021 | 1886 | 0.150 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 385 | 0.150 |
Why?
|
Organometallic Compounds | 1 | 2021 | 647 | 0.140 |
Why?
|
RNA Splicing | 1 | 2022 | 903 | 0.140 |
Why?
|
Tumor Microenvironment | 4 | 2024 | 3942 | 0.140 |
Why?
|
Organ Specificity | 1 | 2022 | 1968 | 0.140 |
Why?
|
Jews | 1 | 2019 | 359 | 0.140 |
Why?
|
Female | 25 | 2025 | 396532 | 0.140 |
Why?
|
Genetic Counseling | 1 | 2021 | 634 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 706 | 0.140 |
Why?
|
Middle Aged | 22 | 2025 | 223267 | 0.130 |
Why?
|
Azepines | 1 | 2017 | 329 | 0.120 |
Why?
|
Male | 23 | 2025 | 364154 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2045 | 0.120 |
Why?
|
Medical History Taking | 1 | 2019 | 779 | 0.120 |
Why?
|
Gene Expression Profiling | 4 | 2024 | 9528 | 0.120 |
Why?
|
Review Literature as Topic | 1 | 2016 | 297 | 0.120 |
Why?
|
Pregnancy Outcome | 1 | 2005 | 2971 | 0.120 |
Why?
|
Preoperative Period | 1 | 2016 | 564 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4853 | 0.110 |
Why?
|
Phosphatidylethanolamine Binding Protein | 1 | 2013 | 8 | 0.110 |
Why?
|
Single-Cell Analysis | 2 | 2022 | 2535 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2952 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2023 | 7430 | 0.110 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2005 | 2537 | 0.110 |
Why?
|
Aged, 80 and over | 7 | 2025 | 59548 | 0.100 |
Why?
|
Mutation | 6 | 2024 | 30214 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1639 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 584 | 0.100 |
Why?
|
Genetic Variation | 2 | 2018 | 6613 | 0.100 |
Why?
|
Genetic Testing | 2 | 2022 | 3591 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2022 | 3511 | 0.090 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2017 | 798 | 0.090 |
Why?
|
Treatment Outcome | 9 | 2024 | 65286 | 0.090 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 1 | 2010 | 25 | 0.090 |
Why?
|
Prognosis | 6 | 2024 | 29959 | 0.080 |
Why?
|
Camptothecin | 1 | 2013 | 599 | 0.080 |
Why?
|
Neoplasm Staging | 4 | 2017 | 11218 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2703 | 0.080 |
Why?
|
Adult | 15 | 2025 | 223305 | 0.080 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2010 | 79 | 0.080 |
Why?
|
Esophagogastric Junction | 1 | 2012 | 350 | 0.080 |
Why?
|
Thalidomide | 1 | 2015 | 886 | 0.080 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 2901 | 0.080 |
Why?
|
STAT3 Transcription Factor | 1 | 2013 | 872 | 0.080 |
Why?
|
North America | 2 | 2024 | 1287 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3552 | 0.080 |
Why?
|
Immunohistochemistry | 1 | 2022 | 11062 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3235 | 0.070 |
Why?
|
Colorectal Neoplasms | 2 | 2024 | 6965 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2018 | 6853 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1762 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3600 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8623 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2021 | 10451 | 0.060 |
Why?
|
Pyrimidines | 1 | 2017 | 3043 | 0.060 |
Why?
|
Disease Progression | 1 | 2022 | 13642 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2057 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2015 | 1960 | 0.060 |
Why?
|
Human papillomavirus 16 | 1 | 2024 | 268 | 0.050 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2015 | 2329 | 0.050 |
Why?
|
Claudins | 1 | 2023 | 116 | 0.050 |
Why?
|
Neoplasm Metastasis | 2 | 2024 | 4892 | 0.050 |
Why?
|
Colonic Neoplasms | 1 | 2013 | 2535 | 0.050 |
Why?
|
Mitotic Index | 1 | 2021 | 160 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2024 | 6514 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 633 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 18076 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8045 | 0.040 |
Why?
|
Age Distribution | 1 | 2005 | 2869 | 0.040 |
Why?
|
Gene Amplification | 1 | 2024 | 1088 | 0.040 |
Why?
|
Survival Analysis | 3 | 2020 | 10101 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2023 | 81657 | 0.040 |
Why?
|
Young Adult | 3 | 2021 | 59939 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2005 | 2741 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1741 | 0.040 |
Why?
|
Neoplasms | 2 | 2017 | 22350 | 0.040 |
Why?
|
Antigens, Bacterial | 1 | 2023 | 1148 | 0.040 |
Why?
|
Purines | 1 | 2021 | 615 | 0.040 |
Why?
|
Prospective Studies | 4 | 2023 | 54872 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2201 | 0.030 |
Why?
|
Aminopyridines | 1 | 2021 | 577 | 0.030 |
Why?
|
Biological Transport | 1 | 2021 | 2083 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1852 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 4050 | 0.030 |
Why?
|
Transcription, Genetic | 2 | 2024 | 7612 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5690 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2023 | 2426 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2016 | 896 | 0.030 |
Why?
|
Cytokine Receptor gp130 | 1 | 2013 | 66 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2056 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 605 | 0.030 |
Why?
|
Disease Management | 1 | 2024 | 2533 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6507 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2030 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2024 | 2598 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2715 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 428 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2023 | 39312 | 0.030 |
Why?
|
Niacinamide | 1 | 2015 | 419 | 0.030 |
Why?
|
Janus Kinases | 1 | 2013 | 253 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2024 | 8540 | 0.020 |
Why?
|
Polyglutamic Acid | 1 | 2012 | 46 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2228 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2015 | 533 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2023 | 4523 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1492 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4652 | 0.020 |
Why?
|
Esophagitis | 1 | 2012 | 164 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2023 | 3108 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2039 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2023 | 3833 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1752 | 0.020 |
Why?
|
Medical Oncology | 1 | 2021 | 2340 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2050 | 0.020 |
Why?
|
Nausea | 1 | 2012 | 681 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3957 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2022 | 4787 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2659 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3610 | 0.020 |
Why?
|
Esophagectomy | 1 | 2012 | 478 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1902 | 0.020 |
Why?
|
Vincristine | 1 | 2010 | 1040 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12536 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81898 | 0.020 |
Why?
|
Alleles | 1 | 2017 | 6896 | 0.020 |
Why?
|
Adolescent | 3 | 2015 | 88902 | 0.020 |
Why?
|
Cisplatin | 1 | 2012 | 1656 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22248 | 0.020 |
Why?
|
Prednisone | 1 | 2010 | 1566 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 17089 | 0.010 |
Why?
|
Phenotype | 1 | 2023 | 16722 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22351 | 0.010 |
Why?
|
Fatigue | 1 | 2012 | 1555 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10745 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10263 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2010 | 2234 | 0.010 |
Why?
|
Signal Transduction | 2 | 2020 | 23618 | 0.010 |
Why?
|
Patient Selection | 1 | 2016 | 4252 | 0.010 |
Why?
|
Pregnancy | 1 | 2005 | 30236 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3226 | 0.010 |
Why?
|
HIV Infections | 1 | 2010 | 17532 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2229 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 74889 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8310 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9407 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10863 | 0.010 |
Why?
|
Animals | 2 | 2024 | 168939 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 13036 | 0.010 |
Why?
|
Protein Binding | 1 | 2013 | 9326 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41706 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7585 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 16044 | 0.010 |
Why?
|
Risk Assessment | 1 | 2016 | 24299 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2019 | 21162 | 0.010 |
Why?
|
United States | 1 | 2016 | 72945 | 0.000 |
Why?
|
Child, Preschool | 1 | 2010 | 42577 | 0.000 |
Why?
|
Child | 1 | 2010 | 80670 | 0.000 |
Why?
|
Concepts
(207)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(97)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_